Bristol-Myers Squibb heads into its July 30 earnings print with options positioning unusually skewed toward calls — a notable shift for a stock that has otherwise drifted quietly lower.
The clearest signal this week is in the options market. The put/call ratio has dropped to 0.78, nearly two standard deviations below its 20-day average of 0.86 — a reading close to the 52-week low of 0.72. That's a meaningful tilt toward call buying, suggesting options traders are leaning more constructive than at almost any point in the past year. The move is especially notable given the stock's mild softness: BMY closed at $55.92, down about 1% on the week and off roughly 2% over the past month. Calls are accumulating while the stock slides, which sets up an interesting divergence ahead of the Q2 report.
Short interest tells a much quieter story, and it probably shouldn't hijack the narrative. At 2.2% of the free float, the bear camp is modest by any measure. The headline — a 36% jump in shares short over the past 30 days — sounds dramatic, but it takes SI from roughly 1.6% to 2.2% of float, which is the definition of going from negligible to still negligible. Borrow conditions confirm there's no real squeeze dynamic: availability is extremely loose at over 6,000% of outstanding short interest, meaning lenders hold roughly 60 shares for every one already borrowed. Cost to borrow has ticked up 50% on the week to 0.63%, but that's still well within easy-borrow territory. The short score of 34 is subdued.
The Street remains broadly constructive, though the most recent analyst activity dates from early April and should be read as background colour rather than fresh conviction. Targets from the most active names cluster between $60 and $75, against a consensus mean of $63 — implying roughly 13% upside from current levels. Bulls point to immuno-oncology leadership, Eliquis durability, and expanding CELMoD franchise optionality. Bears flag US market concentration and the execution risk around several Phase 3 readouts due in 2026. One factor score stands out: BMY ranks in the 92nd percentile for analyst recommendation divergence, which typically signals the bull-bear debate is more charged than the neutral-looking consensus implies. The dividend score of 99 reflects a payout that remains a core part of the investment case, though the most recent dividend data in the snapshot is stale and should not be relied upon for current yield figures.
JP Morgan Asset Management stands as the most active institutional mover among the top holders, adding nearly 13 million shares in its latest reported period — a position build that puts it at roughly 3.8% of shares outstanding. BlackRock holds the largest stake at 8.4%, adding modestly. The institutional base looks stable and passively skewed, with no obvious forced-selling signal.
Earnings reactions have been muted in recent quarters. The Q1 print in early May saw a 1.4% drop on the day and roughly 1.6% over the week following the release. The prior quarter's report produced a small bounce of 1.1% on the day but gave it back and more over the following five days. The pattern points to a stock that tends to absorb earnings without dramatic moves in either direction — which may partly explain why call buyers are willing to lean in without paying up for volatility.
With Q2 results six weeks away, the tension worth watching is whether the call-side options buildup reflects genuine fundamental optimism around pipeline catalysts — or simply income-oriented positioning against a high-dividend name in a low-volatility tape.
See the live data behind this article on ORTEX.
Open BMY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
